Director-Affiliated Entity Sells $26.6M of Liquidia Stock Near 52-Week High
LQDA has more than doubled off its 52-week low of $11.85.
Summary
A director-affiliated entity sold $26.6 million in Liquidia Corp stock, executing on previously filed intentions to sell while the stock is trading near its 52-week high.
Key Events · Ownership and Investor Activity · LQDA
-
Significant Insider-Affiliated Sale
A director-affiliated entity, Canaan VIII L.P., sold 388,223 shares of Liquidia Corp common stock for a total of $26,634,789.
-
Timing Near 52-Week High
The sales occurred between $64.48 and $72.41 per share, close to the company's 52-week high of $72.705, indicating profit-taking.
-
Execution of Prior Intent
These sales follow a series of Form 144 filings by Canaan VIII L.P. in May and June, signaling intent to sell shares.
-
Director Disclaimer
The reporting director, Stephen M. Bloch, disclaims direct participation in the investment decision, noting the sales were made by Canaan VIII L.P.
Analysis · LQDA · Life Sciences
A director-affiliated entity, Canaan VIII L.P., executed significant sales of Liquidia Corp common stock totaling $26.6 million. While the reporting director disclaims direct participation in the investment decision, these sales represent a substantial reduction in holdings by an entity closely associated with the board. The transactions occurred as the stock trades near its 52-week high, suggesting the entity is realizing gains. This follows a pattern of recent Form 144 filings by Canaan VIII L.P. indicating intent to sell.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $71.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $11.85 to $72.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.